All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How can venetoclax combinations improve outcome for FLT3-mutant AML?

During the 63rd ASH Annual Meeting and Exposition, the AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How can venetoclax combinations improve outcome for FLT3-mutant AML?

How can venetoclax combinations improve outcome for FLT3-mutant AML?

Daver begins by outlining some of the successes seen in venetoclax therapies, discussing studies on venetoclax combinations such as VIALE-A and ADMIRAL. He goes on to discuss outcomes of venetoclax + gilteritinib combinations, with promising remission rates and molecular clearance rates.